Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

Bone Marrow Transplantation

Volumn 50, Issue 2, 2015, Pages 197-203

  Bachanova, V ^a   Burns, L J ^a   Wang, T ^b   Carreras, J ^b   Gale, R P ^c   Wiernik, P H ^d   Ballen, K K ^e   Wirk, B ^f   Munker, R ^g   Rizzieri, D A ^h   Chen, Y B ^e   Gibson, J ⁱ   Akpek, G ^j   Costa, L J ^k   Kamble, R T ^l   Aljurf, M D ^m   Hsu, J W ⁿ   Cairo, M S ^o   Schouten, H C ^p   Bacher, U ^q,r   Savani, B N ^s   Wingard, J R ^n,t   Lazarus, H M ^u   Laport, G G ^v   Montoto, S ^w   Maloney, D G ^x   Smith, S M ^y   Brunstein, C ^a   Saber, W ^b   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Barts and the London   (United Kingdom)

^d OUR LADY OF MERCY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^g Louisiana State University Health Sciences Center at Shreveport   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^j Banner MD Anderson Cancer Center   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

ⁿ UNIVERSITY OF FLORIDA   (United States)

^o NEW YORK MEDICAL COLLEGE   (United States)

^p MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^q UNIVERSITY OF HAMBURG   (Germany)

^r MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^s VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^t LifeSouth Community Blood Centers   (United States)

^u UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^v STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^w ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^x USA   (United States)

^y UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; TACROLIMUS; THYMOCYTE ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; FEMALE; FOLLOW UP; HLA MATCHING; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEUTROPHIL; NON RELAPSE MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE BODY RADIATION; ACUTE DISEASE; ADOLESCENT; AGE; ALLOGRAFT; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RISK FACTOR; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ALLOGRAFTS; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; UNRELATED DONORS;

EID: 84922404159     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.259     Document Type: Article

References (33)

1. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
2. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
3. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: Long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 554-563.
4. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16: 35-45.
5. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-5536.
6. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
7. Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillian M, DeFor TE et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 538-545.
8. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ et al. Alternate donor hematopoietic cell transplantation (HCT) in non-hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012; 18: 1036-1043.
9. Rodrigues CA, Rocha V, Dreger P, Brunstein C, Sengeloev H, Finke J et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 2014; 99: 370-377.
10. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory hodgkin's lymphoma: an analysis from the lymphoma working party of the european group for blood and marrow transplantation. J Clin Oncol 2008; 26: 455-462.
11. Anasetti C, Aversa F, Brunstein CG. Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? Biol Blood Marrow Transplant 2012; 18: S161-S165.
12. Brunstein CG, Laughlin MJ. Extending cord blood transplant to adults: dealing with problems and results overall. Semin Hematol 2010; 47: 86-96.
13. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
14. Ballen KK, Klein JP, Pedersen TL, Bhatla D, Duerst R, Kurtzberg J et al. Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2012; 18: 903-912.
15. Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ et al. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009; 15: 214-222.
16. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced hodgkin lymphoma. Blood 2006; 107: 3804-3807.
17. Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D et al. Impact of disease status and stem cell source impact on the results of reduced intensity conditioning transplant for hodgkin lymphoma: a retrospective study from the french society of bone marrow graft transplantation and cellular therapy. Haematologica 2013; 98: 1467-1475.
18. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011; 46: 659-667.
19. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15: 109-117.
20. Avivi I, Canals C, Vernant JP, Wulf G, Nagler A, Hermine O et al. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. Bone Marrow Transplant 2014; 49: 671-678.
21. Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Viña M et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant 2008; 14(9-Suppl): 37-44.
22. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reducedintensity conditioning regimen workshop: defining the dose spectrum. report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
23. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P et al. 1995 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Zhang X, Loberiza FR Jr, Klein J, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007; 88: 95-101.
26. Zhang X, Loberiza FR, Klein JP, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed 2011; 101: 87-93.
27. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data, 2nd edn, Springer Verlag: New York, USA, 2003.
28. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ et al. Alternate donor hematopoietic cell transplantation (HCT) in non-hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012; 18: 1036-1043.e1.
29. Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the lymphoma working party of the EBMT. Bone Marrow Transplant 2013; 48: 1409-1411.
30. Fernandez-Viña MA, Wang T, Lee SJ, Haagenson M, Aljurf M, Askar M et al. Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood 2014; 123: 1270-1278.
31. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923-1930.
32. Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M et al. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood 2013; 122: 3651-3658.
33. Spellman SR, Eapen M, Logan BR, Mueller C, Rubinstein P, Setterholm MI et al. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood 2012; 120: 259-265.